Guardant Health Q4 2024 Adj. EPS $(0.62) Beats $(0.74) Estimate, Sales $201.814M Beat $192.141M Estimate
GHFebruary 20, 2025
Read more →Viz.ai Reveals Proposed Collaboration With Guardant Health
GHJanuary 14, 2025
Read more →Guardant Health Announced Preliminary FY2024 Sales Of Approximately $737M, An Increase Of 31% Compared To Consensus Of $723.9M
GHJanuary 13, 2025
Read more →Guardant Health Announced Preliminary Q4 Sales Of Approximately $200M, An Increase Of 29% Compared To Consensus Of $186.73M
GHJanuary 13, 2025
Read more →COTA Announces A New Partnership With Guardant Health That Will Allow Biopharmaceutical Researchers To Access The Combined Resources Of COTA's Research-grade Electronic Health Record Data From Academic And Community Care Centers And Guardant's Clinicogeno
GHDecember 19, 2024
Read more →Guardant Health Raises FY24 Revenue From $690M-$700M To $720M-$725M Vs $695.221M Est.
GHNovember 6, 2024
Read more →Guardant Health Q3 2024 Adj. EPS $(0.45) Beats $(0.74) Estimate, Sales $191.500M Beat $170.625M Estimate
GHNovember 6, 2024
Read more →What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
GHFDA staff reviewers raise concerns over Guardant Health's experimental Shield blood test for colorectal cancer, citing low sensitivity in detecting certain tumor types. Shield aims to improve early CRC detection and compliance, potentially extending patient survival.
May 21, 2024
Read more →Guardant Health Receives EU IVDR Certification For Its Guardant360 CDx Blood Test
GHMay 21, 2024
Read more →Guardant Health's Real-World Data Supporting Performance Of Shield Blood Test For CRC Presented At 2024 Digestive Disease Week
GHMay 16, 2024
Read more →Guardant Health Announces Shield Blood Test Available In U.S. To Detect Early Signs Of Colorectal Cancer In Average-Risk Adults
GHMay 2, 2022
Read more →